Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by SunnyGulfBeachon Mar 12, 2015 3:12pm

622 Views

Post# 23515105

RE:Full breakout mode

I have been an owner of RVX since 2008. I remember $8.00 and also remember 15 cents 2 summers ago. The one thing that has kept me as a shareholder since the beginning is back when I first got involved seeing DM on BNN and being impressed with him at the time. Made me buy more that day. I also remember one of the wiser posters on this site commenting back then…” RVX will make a few shareholders very very rich”. I’m in whatever happens. Good luck to all……..

Bullboard Posts

Advancing flagship Ishkõday Gold Project in Ontario